Ординатура / Офтальмология / Английские материалы / Clinical Ocular Pharmacology 5th edition_Bartlett, Jaanus_2008

Index

767

Cell membrane, 186-187

Child—cont’d

Cell wall synthesis, antibacterial drugs

cycloplegic refraction in, 343

syndrome, 359-360

affecting, 179-186

preseptal cellulitis in, 392f

Cholinergic innervation, 125, 126f

bacitracin as, 185

pupil dilation in, 334

Cholinergic overdose, 666

cephalosporins as, 183-185

special considerations for, 11-12, 11f

Chondroitin sulfate, 268

penicillins as, 179-183. See also

tropicamide and, 134, 137

Penicillin

visceral larva migrans in, 629

vancomycin as, 185-186

Chlamydia trachomatis

Choroidal neovascularization

CellCept, 595

azithromycin for, 192

anecortave for, 310

Cell-mediated immunity, 247

doxycycline for, 190

Cellular debris, 591

erythromycin for, 191

ranibizumab for, 306-307

Cellulitis

hyperacute conjunctivitis with, 450

in retinal disease, 619-620

orbital, 181

inclusion conjunctivitis with, 456-457,

rostaporfin and, 305

penicillin for, 181, 182

457f

verteporfin and, 304

preseptal, 182, 391-393, 391t, 392f

infections caused by, 177

Choroiditis. See Posterior uveitis

Cellulose ether, 266-268, 267t

Reiter’s syndrome and, 472

Central corneal thickness, 672-673, 673b

trachoma with, 457-458, 458f

Chronic obstructive pulmonary

Central crystalline dystrophy, 485t

Chloramphenicol, 192-193

disease, 163

Central nervous system

adverse effects of, 754t

Chrysiasis, 713

atropine toxicity and, 129

on optic nerve, 737-738

Chymase-containing mast cell, 549

beta-blockers affecting, 148b, 149

for conjunctivitis, 447

Cialis, 729-730

cocaine affecting, 119

formulations of, 186t

contraindications related to, 5

systemic effects of, 9t

Cidofovir, 623b, 623, 717-718, 755t

cyclopentolate and, 132-133

Chlorhexidine, 216t

Ciliary body, structure of, 23

nonnarcotic drugs affecting, 100

for Acanthamoeba, 215

Ciprofloxacin, 194t

penicillin effects on, 182

effects of, 30

in bullous keratopathy, 494

scopolamine and, 130

toxic conjunctivitis and, 474

in burn injury, 510

Central nervous system depressant

Chlorobutanol, 30

clinical uses of, 195

adverse effects of, on pupil, 719

Chloroquine

for conjunctivitis, 448

in anisocoria evaluation, 352t

adverse effects of, 750t

for contact lens-related

as mydriatic agent, 119

on conjunctiva, 713

complications, 540

as topical anesthetic, 87-88, 88t

on cornea, 704t, 705

for corneal ulcer, 523, 524

Central nervous system stimulant, 718,

retinal, 725-728, 725t, 726f, 727t

for foreign body, 500

718b

in systemic lupus erythematosus, 471

formulations of, 186t

Central retinal vein occlusion, 632, 634

Chlorpheniramine, 561

for infectious conjunctivitis, 446

Centrally acting agent, 98

Chlorpromazine

Cephalosporin, 183-185, 184t

adverse effects of, 756t

in recurrent corneal erosion, 507

for bacterial dacryoadenitis, 424

on conjunctiva, 712, 712t

Circadian rhythm of intraocular

for internal hordeolum, 390

on cornea, 704t

pressure, 672-673, 686-687

in preseptal cellulitis, 391

on eyelid, 712, 712t

Citrate, 511

Ceptaz, 184t

on lens, 704t

Claforan, 184t

Certification, 63-64

antimuscarinic dosage of, 721t

Clarinex, 252t, 552t

Cervicitis, 192

lens opacity caused by, 708-709, 708t,

for seasonal conjunctivitis, 561

Cetirizine, 250, 252t, 253, 552t, 561

7009f

Clarithromycin, 447

adverse effects of, 753t

Chlorpropamide, 194

Claritin, 252t, 552t

eye movement caused by, 719-720

Chlor-Trimeton, 251t, 551t

Clark’s rule for pediatric dosage, 11

Chalazion, 390-391

Chocolate agar, 441

anesthesia for drainage of, 327, 327f

Cholestatic hepatitis, erythromycin-

Cleanser, eyelid, 45

Chamomile, 741, 758t

induced, 192

Clear Eyes, 248t

Chelation, 495

Choline-magnesium salicylate, 102t

Clemastine, 251t

Chemical burn, 479

Cholinergic agonist

Clodronate, 753t

corneal, 509-511, 510f, 510t

classification of, 167b

Clomiphene, 751t

Chemical cautery, 409

myopia caused by, 721

retinal, 731

Chemical property of tears, 17-19, 18f

pilocarpine as, 168-170, 168t, 171b

Clonazepam, 377

Chemosis, 440t

Cholinergic antagonist

Chemotherapy, conjunctival effects

atropine as, 126, 127t, 128-129

Cloxacillin, 180t

of, 713

cyclopentolate as, 130-133, 131f, 132b

Chickenpox, 393

homatropine as, 129-130

and, 353

Child

overview of, 125-126

Cocaine

administering topical drug to, 41

scopolamine as, 130

corneal effects of, 711

atropine overdose in, 129

tropicamide as, 133-137, 133f, 134f,

pupil and, 718

cyclopentolate for, 132

135t, 136f

Cocci, gram-negative, 177

768

Index

Cod liver oil, 298t

Conjunctiva—cont’d

Codeine

adverse effects on, 7t

for child, 109t

anatomy of, 437-438, 438f

formulations of, 105t

anesthesia for surgery on, 323

pharmacological properties of, 104,

atopic dermatitis and, 466-467, 466f

104t

cataract surgery complications of, 604

for severe pain, 109-110

in connective tissue disease, 470-474

Cogan’s syndrome, 516t

polyarteritis nodosa and, 471-472,

Cogentin, 721

472f

Cognitive history, 4t, 6

Reiter’s syndrome and, 472-474, 473f

Colitis, antibiotic-associated

systemic lupus erythematosus,

pseudomembranous, 184

470-471, 471f

Collaborative Initial Glaucoma

immunology of, 549

Treatment Study, 695t

inflammation of, 439-440, 474-478

Collaborative Normal-Tension Glaucoma

in phlyctenulosis, 474-475, 475f

Study, 695t

in pinguecula, 476, 476f

Collagen plug, 273-274, 273f, 273t, 427

pterygium and, 477-478, 477f

Collagen shield, 46-47, 46f

signs of, 440t

Collagen vascular disorder, 580

in superior limbic kerato-

Collarette, 383, 383f

conjunctivitis, 475-476, 476f

Colloidal system as vehicle, 34

microbiologic features of, 438-439,

Collyrium Fresh, 248t

439b

Color vision, cardiac glycosides and, 729

mucous membrane disorder of,

Comanagement, 64-65, 64b

467-470

Combination agent

cicatricial pemphigoid and, 467-469,

for cataract surgery, 601

467f, 468f

for pupil dilation, 333-334

in erythema multiforme major,

topical carbonic anhydrase inhibitor

469-470

and, 167

in Stevens-Johnson syndrome,

Combivir, 206t

469-470

Compartment theory, 25-27

in toxic epidermal necrolysis,

Complete blood count in uveitis, 597

469-470

Compliance, 59-60, 60b

in nutritional deficiency, 478

with glaucoma treatment, 695-696

psoriasis and, 465-466, 465f

Complications

rosacea and, 463-465, 464f

of cataract surgery, 604, 606-615.

trauma to, 478-480, 479f

See also Cataract surgery,

Conjunctival compression cytology, 423

complications of

Conjunctival hyperemia

contact lens-related

in atopic keratoconjunctivitis, 567

epithelial microcysts as, 542-545,

decongestants causing, 249

544f

Horner’s syndrome and, 354

infiltrative events as, 538-542, 540f,

latanoprost and, 142

544f

Conjunctival injection, epithelial

of drug use

microcysts and, 543

diagnostic, 75-76

Conjunctival phlyctenule, 517

therapeutic, 76-78

Conjunctivitis, 444-463

of uveitis, 596-597

acute bacterial, 444-449, 445f, 446f

Compress

diagnosis of, 445-446

for atopic dermatitis of eyelid, 570

etiology of, 444-445

in eyelid hygiene, 384

management of, 446-449, 449f

for urticaria, 572

allergic, 239-240, 550, 556t-559t,

Computed tomography

560-568

in myasthenia gravis, 375, 375f

atopic keratoconjunctivitis,

in thyroid-related orbitopathy,

567-568, 567f

650-651, 651f

giant papillary, 561-564, 562t, 563f

Confocal scanning laser

medrysone for, 228

ophthalmoscopy, 679, 679t

seasonal, 550, 560-561, 560f

Congenital epiphora, 429-430

vernal keratoconjunctivitis,

Congestive orbital disease, 647-648, 648f

564-566, 565f

Conjunctiva, 437-482, 550, 556t-559t,

antibacterial drugs for, 176t

560-568. See also Conjunctivitis

chronic bacterial, 451

adverse drug effects on, 711-713, 712t

decongestants causing, 249

770

Index

Cycloplegic agent—cont’d

Cytomegalovirus—cont’d

Dermatitis—cont’d

for herpes zoster ophthalmicus, 533

intravitreal drug administration for,

conjunctivitis and, 466-467, 466f

homatropine as, 129-130

50-51

of eyelid, 568, 569t, 570

overview of, 125-126

necrotizing herpetic retinopathy and,

contact, 550, 570-571, 571b, 571f

for pseudophakic cystoid macular

621-624, 621f, 622f, 622t

ointment causing, 44

edema, 614

D

sulfonamides and, 194

in Reiter’s syndrome, 473

varicella zoster causing, 395

scopolamine as, 130

Dacryoadenitis, 424, 424f

Dermatologic system. See Skin entries

selection of, 345

Dacryocystitis

Dermatosis, periorbital, 568

for strabismus, 663-665

acquired, 433-434

Descemet’s membrane, 483

toxic keratitis and, 514

antibacterial drugs for, 176t

Desloratadine, 250, 252t, 253, 552t

tropicamide as, 133-137, 133f, 134f,

penicillin for, 182

for seasonal conjunctivitis, 561

135t, 136f

Dandruff, 385

Desomedine, 215

for uveitis, 594

Dapiprazole, 120-121, 120f, 121f, 654

Detachment, retinal. See Retinal

Cycloplegic refraction, 343-348

Dapsone, 468

detachment

administration of drug for, 346-347

Daranide, 755t

Dexamethasone

agents for, 345-346, 345t

Dark in anisocoria, 349, 351f

clinical uses of, 227-228

comparison of agents for, 345-346

Darunavir, 206t

for corneal ulcers, 525

disadvantages of, 344

Datura, 361-362, 741, 758t

formulations of, 227t

indications for, 343-344, 344b

Daypro, 102t

ocular hypertension caused by, 231

precautions for, 344

adverse effects of, 751t

for pseudophakic cystoid macular

spectacle prescribing and, 347-348

Deafness, vancomycin causing, 185-186

edema, 614

techniques of, 347

Death, atropine causing, 129

Dexedrine, 718

Cycloplegic spray, 43

Debridement, anesthesia for, 323

Diabetic macular edema, 632, 633-634

Cyclosporine A, 236-240, 237f, 238f,

Decompression in thyroid-related

Diamox, 755t

239f, 555t

orbitopathy, 657, 660-661, 660f

Diazepam, 377

in allergic disease, 550

Decongestant, 247, 248t, 249

Dichlorphenamide

animal studies of, 240

in seasonal conjunctivitis, 560

adverse effects of, 755t

in atopic keratoconjunctivitis,

Deep lamellar endothelial keratoplasty,

pharmacokinetic properties of, 161t

567-568

490f

Diclofenac, 235

clinical uses of, 240

Delamination, corneal, 507

clinical uses of, 235-236

contraindications to, 242

Delavirdine, 206t

for corneal abrasion, 496

for dry eye, 239, 240-241

Delayed hypersensitivity reaction, 580

in cystoid macular, 633

human studies of, 240-241

Delivery system, 4, 39-52, 703

in episcleritis, 578

for immune-mediated disease, 241-242

intracameral, 50

in exposure keratopathy, 509

in myasthenia gravis, 376

intravitreal, 35t, 50-51, 51f

for foreign body, 501

pharmacology of, 236-240, 237f, 238f,

periocular, 48-50, 49f, 50b, 50f

photorefractive keratectomy and, 236

239f

photodynamic therapy as, 51

for pseudophakic cystoid macular

for psoriasis, 465

topical, 39-48. See also Topical

edema, 614

in scleritis, 584

administration

for uveitis, 595

side effects of, 242

Dellen, corneal, 512-513, 513f

Dicloxacillin

for tear stimulation, 275-276, 429

Demodex, 383, 383f

in preseptal cellulitis, 391

for uveitis, 595

Demodex brevis, 397

spectrum of activity of, 180t

in vernal keratoconjunctivitis, 566

in chalazion, 390

Didanosine, 206t

Cyproheptadine, 377

Demodex folliculorum, 397

Didrocal, 753t

Cyst

rosacea and, 388

Dietary reference intake, 295

Acanthamoeba, 215, 537

in seborrheic blepharitis, 385

Dietary supplement, 295-301

of eyelid, 401-402, 401f

Demyelinating optic neuropathy, 369-370

adverse reactions and, 703

Cystoid macular edema, 632-635, 633f

Dendritic lesion

Dietary Supplement Health and

after cataract surgery, 613-614, 614f

in herpes simplex keratitis, 528

Education Act, 295

ketorolac for, 236

in herpes zoster ophthalmicus, 531f

Diethylcarbamazine, 630

latanoprost and, 142-143

Dendritiform epitheliopathy, 143

Diffuse anterior scleritis, 580, 580f

nonsteroidal anti-inflammatory drugs

Denervation hypersensitivity in Adie’s

Diffusion, 25-26

and, 234-235

syndrome, 359

Diflunisal, 102t, 595

Cytokine

Depigmentation, steroid-induced, 390-391

Digitoxin, 729, 748t

cyclosporine A and, 236-237

Deposit, tetracycline, 713

Digoxin, 729, 748t

dry eye and, 264-265

Depressant, on pupillary effects of, 719

Diisopropyl fluorophosphate, 666

in uveitis, 588

Depression

Dilation of pupil, 329-341

Cytokine antagonist, 660

bone marrow, 192

anterior angle evaluation before,

Cytology, conjunctival compression, 423

respiratory, 107

330-333

Cytomegalovirus

Dermatitis

gonioscopy for, 332-333, 333f, 333t

antiviral drugs for, 204

atopic

shadow test in, 330, 331f

772

Index

Dye—cont’d

Electroretinography, 726

lissamine green as, 290-291, 291f

Elestat, 258t, 553t

methylene blue as, 292

Elidel, 555t

rose bengal as, 289-290, 289f, 290f

for atopic dermatitis of eyelid, 570

Dynamic contour tonometry, 674

ELISA

Dyscrasias, blood

in conjunctival inflammation,

acetazolamide causing, 162

443-444

sulfonamides causing, 193-194

in uveitis, 597

Dysthyroid ophthalmopathy, 644. See also

Emadine, 254t, 551t

Thyroid-related orbitopathy

in seasonal conjunctivitis, 560

Dystrophy and degeneration, corneal,

Emedastine, 254t, 255, 551t

484-496

in seasonal conjunctivitis, 560

anterior basement membrane, 486-488,

EMLA, 94

487f

Empiric therapy for conjunctivitis, 442

bullous keratopathy and, 493-494, 493f

Emsam, 690t

calcific band keratopathy and, 494-496,

Emtricitabine, 206t

495f

Emtriva, 206t

classification of, 484t-485t

Enbrel

Fuchs’, 488-490, 489f, 490f

for psoriasis, 465

hydrops secondary to keratoconus

for uveitis, 595-596

and, 490, 491f, 492-493, 492f

Endophthalmitis

E

after cataract surgery, 601

amphotericin B for, 208

Eagle punctal plugs, 273t

antibacterial drugs for, 176t

Early Manifest Glaucoma Trial, 696t

nematode, 629-630

Eaton-Lambert syndrome, 375

in toxocariasis, 629

Echinacea purpurea, adverse effects

Endophthalmos, postoperative, 604,

of, 758t

606-607, 606f

Echinocandin, 208, 214-215

Endothelial dystrophy, Fuchs’, 488-490,

Echothiophate, 666

489f

phenylephrine with, 116

Endothelial growth factor, vascular,

systemic effects of, 9t

310-311

Ectopia lentis, 335

in age-related macular degeneration,

Ectropion, punctal, 432-433

635

Eczema, 567

Endothelial keratoplasty, deep lamellar,

Eczematous conjunctivitis, 550

490f

Edema

Endothelium

cystoid macular

in bullous keratopathy, 493-494

after cataract surgery, 613-614, 614f

corneal, 483

latanoprost and, 142-143

dorzolamide and, 165

in episcleritis, 578

structure of, 22

Edinger-Westphal nucleus, 125

Enfurvirtide, 207t

Edrophonium in myasthenia gravis, 374

Enlargement of lacrimal gland, 424

Education, patient, 60-61

Enlon test for myasthenia gravis, 374

on antibacterial treatment, 177

Enoxacin, 194t

on cataract surgery, 601

Enterobacter

importance of, 3-4

aminoglycosides for, 187

Efavirenz, 206t

infections caused by, 178t

Efferent pupillary pathway, 349

penicillin for, 182

Effusion, choroidal, postoperative, 607

Enterovirus, 459

Eicosapentaenoic acid synthesis

Enzyme in ciliary body, 23

pathway, 235f

Enzyme-linked immunosorbent assay

Eight ball clot, 611

in conjunctival inflammation,

Elderly patient

443-444

administering topical drug to, 42

in uveitis, 597

pain management in, 110

Eosinophil

special considerations for, 12-13

in allergic eye disease, 550

toxoplasmosis in, 628

in toxocariasis, 629-630

Electrolyte in artificial tears, 269

Epidemic keratoconjunctivitis, 452, 452f,

Electromyography

453t, 525-527, 526f

in myasthenia gravis, 374

Epidermal keratinization, 271

in thyroid disease, 649

Epidermal necrolysis, toxic, 469-470

774

Index

Fluorescein sodium—cont’d

Forme fruste, 565

Gastrointestinal system—cont’d

for angiography, 287-288

Form-Fit intracanalicular plug, 273t, 429t

penicillin effects on, 182

for angioscopy, 288

Formulation, drug

tetracyclines affecting, 190

for applanation tonometry, 286, 287t

compartment theory and, 25-27, 26f

Gatifloxacin, 195

for contact lens management, 285-286

development of, 36

for conjunctivitis, 448, 449

contraindications to, 288

ocular tissue structure affecting, 17-15

for corneal ulcers, 523-524

excitation and emission spectra of, 284f

aqueous humor, 23

formulations of, 186t

for fluorophotometry, 288

blood supply in, 25

for pathogens susceptible to, 442t

intravenous applications of, 287-288

chemical properties of tears and,

Gaze nystagmus test, alcohol, 720

for lacrimal system evaluation, 286

17-19, 18f, 19f

Gel, 45

for ocular surface integrity testing,

ciliary body, 23

Gel-forming agent, 33

284-285

cornea and sclera, 19-22, 19f, 20f,

Gemifloxacin, 194t, 195

pharmacology of, 283

21f, 21t

Gender

preparations of, 284t

iris and, 22

in adverse drug reaction, 703

structure of, 283f

retina and optic nerve, 24-25

uveitis and, 589

topical applications of, 284-286, 284t,

vitreous humor, 23-24

General contact lens-related papillary

285f, 286f

Fornix conjunctiva, 437, 438f, 480

conjunctivitis, 563

Fluorescent antibody smear, 443

Fortovase, 207t

Generic drug, 58-59

Fluorometholone, 555t

Foscarnet

Gentamicin

clinical uses of, 228

for cytomegalovirus retinitis, 622-623,

clinical uses of, 188

in episcleritis, 578

622b

formulations of, 186t

formulations of, 227t

for progressive outer retinal necrosis,

steroids with, 188t

ocular hypertension and, 231

625-626

for corneal ulcer, 523

in vernal keratoconjunctivitis, 566

FP receptor, 139

for infectious conjunctivitis, 446

Fluorophotometry, vitreous, 288

Friction sweat test, 354

for pathogens susceptible to, 442t

Fluoroquinolone, 194-196, 194t

Fuchs’ dystrophy, 485t, 488-490, 489f

Gentamicin-prednisone, 464

in burn injury, 510-511

Fundus examination

GenTeal, 267t, 427t

cataract surgery and, 601

in anterior uveitis, 591

Giant papilla in vernal

clinical uses of, 194-195

in intermediate uveitis, 592

keratoconjunctivitis, 564

for conjunctivitis, 448, 449

in posterior uveitis, 593

Giant papillary conjunctivitis, 549

for contact lens-related

Fungal infection

contact lens-related, 542f, 556t, 558t,

complications, 540

amphotericin B for, 208

561-564, 562t, 563f

contraindications to, 196

conjunctival, 439b

loteprednol etabonate for, 228

for corneal ulcer, 523, 524

corneal, 534-536, 535f

mast cell stabilizers for, 255

for infectious conjunctivitis, 446-447

scleritis with, 577b

signs and symptoms of, 562t

pharmacology of, 194

Fuorexon, 89, 288-289, 289f

Giemsa stain, 535

for pterygia, 478

Fusarium, 205, 534

Gingko biloba, 741, 758t

side effects of, 195-196

Fusion inhibitor, 207t

Gland

for Stevens-Johnson syndrome, 469

Fuzeon, 207t

lacrimal. See Lacrimal gland; Lacrimal

for Thygeson’s superficial punctate

G

system

keratitis, 534

meibomian. See Meibomian gland;

5-Fluorouracil, 715

Gallium-67 citrate, 632

Meibomianitis

Flurasafe, 89

Gamma linolenic acid, 233

of Moll, 263

Flurbiprofen

Ganciclovir, 204

sebaceous, carcinoma of, 404, 404f

in cystoid macular, 633

for cytomegalovirus retinitis, 622-623,

thymus, 373

formulations of, 236t

622b

of Zeis, 263

Folate metabolism, 193-194

intravitreal administration of, 51

Glaucoma, 671-698

Folic acid deficiency, 300

intravitreal implant with, 34, 36

angle-closure, 693-694

Follicular conjunctivitis, 439-440, 440t

for progressive outer retinal necrosis,

atropine and, 129

decongestants causing, 249

625-626

risk of pupil dilation and, 67

in pharyngoconjunctival fever, 452

Gastrointestinal disorder

tropicamide and, 137

Fomivirsen, 623

acetaminophen and, 103

examination of, 671-685

Food and Drug Administration

aspirin and, 100

gonioscopy in, 674-676

on bioequivalency, 58-59

NSAIDs and, 103

of intraocular pressure, 671-674,

drug reaction form of, 742f-743f

opioid and, 107

673b, 674b

Forced duction test, 320-321, 321f

in child, 110

of optic nerve head and retinal

Foreign body

in elderly, 111

nerve fiber, 676-678, 678f

anesthesia for removal of, 322-323

Gastrointestinal system

of topic nerve hemorrhages,

conjunctival, 478-479, 479f

azithromycin and, 192

678-680

corneal, 498-502, 498f-502f

beta-blockers affecting, 148b

of visual fields, 680-685, 681f-684,

Form for reporting drug reaction,

cephalosporins affecting, 184

685b

742f-745f

fluoroquinolones affecting, 195

historical perspective on, 671

Index

775

Glaucoma—cont’d

Gram-positive bacteria

Hematoporphyrin, 303

hypotensive drugs for, 139-173, 141b.

as conjunctival pathogen, 439b

See also Hypotensive drug

infections caused by, 177

Hemoglobinopathy, 163

inflammation with, 694-695, 694b

Granular type I dystrophy, 484t

Hemolytic anemia, 193-194

neovascular, 693

Granule, pigment, of iris, 22

Hemorrhage

pigmentary, pupil dilation in, 335

Granuloma

optic nerve, 678-679

pupillary block, risk of pupil dilation

in sarcoidosis, 630, 632

retinal, in sarcoidosis, 632

and, 67

in toxocariasis, 629

Hemorrhagic conjunctivitis, 527

steroid-induced inflammatory, 596

Granulomatous disease, 590

treatment of, 685-694, 687-694,

Graves hyperthyroidism, 643-662. See

Herbal medication

695t-696t

also Thyroid-related orbitopathy

adverse reactions and, 703

alpha-adrenergic agonists in, 690,

Groenouw dystrophy, 484t

safety of, 301

690t

Growth factor, vascular endothelial,

beta-adrenergic agonists in, 689-

310-311

Herpes simplex virus infection

690, 689b, 689t

in age-related macular degeneration,

carbonic anhydrase inhibitors in,

635, 638

conjunctivitis as, 454-455, 455f

691, 691b, 691t

Guanethidine, 654

compliance with, 696-697

Guidelines

interstitial keratitis in, 516t

hyperosmotics in, 694

for antimicrobial drug, 175-176, 176b

keratitis with, 527-530, 528f, 530f

indications for, 685-686

for antiviral drugs, 198t-200t

monocular trials in, 686-687

Guttata in Fuchs’ dystrophy, 488-490,

396f

parasympathomimetics in, 688-689,

489f

688t

H

prostaglandins for, 687t, 688

Herpes zoster virus infection

risk analysis in, 686

H1 antihistamine, 249-250, 251t-252t,

drugs for, 201, 202t-203t

strategies for, 691-693

253-255

target intraocular pressure in, 686

adverse effects of, reduced tear

529, 530

trials of, 695t-696t

production, 714

Herpetic infection, canalicular, 433

uveitis and, 596

for postherpetic neuralgia, 396

Herpetic retinopathy, necrotizing,

world impact of, 671

in seasonal conjunctivitis, 560

620-626

Glaucoma Laser Trial, 695t

HAART, 204

Glauctabs, 755t

for cytomegalovirus retinitis, 624

GLIC1A gene, 724

Haemophilus influenzae, 741

621f, 622f, 622t

Globe perforation, 581

azithromycin for, 192

Glucose, 281

in bacterial conjunctivitis, 446

624-626, 625f, 625t

Glycerin, 280-281, 280t

cephalosporin and, 18

Herrick lacrimal plug, 273t

Glycoprotein, 264

clarithromycin for, 192

Heterochromia iridis, 354

Glycosaminoglycan, 231

in conjunctival flora, 438

Hexamidine, 216t

Goblet cell, 437-438

conjunctivitis and, 447, 448

High oxygen-permeable silicone

Gold salts, adverse effects of, 750t

corneal ulcer and, 520

hydrogel contact lens, 497

on conjunctiva, 713

dacryocystitis and, 433

Histamine, 245-247, 246f, 246t

on cornea, 704t, 710, 710f

infections caused by, 177

on lens, 704t

ophthalmia neonatorum and, 462

253-255

Gonioscopy, 674-767

penicillin for, 181-182

for postherpetic neuralgia, 396

for anterior angle evaluation, 332-333,

in preseptal cellulitis, 391, 392

History, patient

333f, 333t

trimethoprim for, 193

importance of, 4-6, 4t

in anterior uveitis, 591

Haloperidol, 377

in intermediate uveitis, 592

Hay fever conjunctivitis, 550. See also

of uveitis, 589

in posterior uveitis, 593

Conjunctivitis, allergic

Gonococcal ophthalmia neonatorum, 190

Healing of corneal epithelium, 232

Hivid, 206t

Gonorrheal dacryoadenitis, 424

Health Canada form for reporting

HLA-B27

Good Samaritan statute, 65

adverse reaction, 744f-745f

psoriasis and, 465

Gram stain

Hearing loss, erythromycin causing, 192

uveitis and, 589

in conjunctival inflammation, 443,

Heart, beta-blockers affecting, 149

Homatropine, 129-130

443t

Hematologic disorder

in fungal keratitis, 535

acetazolamide causing, 162

361-362

Gramicidin, 187

chloramphenicol causing, 192-193

for corneal abrasion, 497

formulations of, 187t

penicillin causing, 182

for corneal ulcers, 524

for pathogens susceptible to, 442t

sickle cell

Gram-negative bacteria

acetazolamide and, 163

for interstitial keratitis, 517

as conjunctival pathogen, 439b

intraocular pressure and, 692-693

preparations of, 127t

infections caused by, 177

sulfonamides causing, 193-194

properties of, 127t

776

Index

Homatropine—cont’d

Hydroxychloroquine—cont’d

Hypertrichosis, 142

for pseudophakic cystoid macular

retinal effects of, 725-728, 725t, 726f,

Hypertrophy, papillary, 439

edema, 614

727t

Hypertropia, in thyroid disease, 648-649

in recurrent corneal erosion, 505

in systemic lupus erythematosus, 471

Hyphema

in Reiter’s syndrome, 473

Hydroxyethylcellulose, 266-268, 267t

acetazolamide and, 163

Homocystinuria, 335

Hydroxypropyl guar, 269

after cataract surgery, 610-611, 610f,

Hordeolum

Hydroxypropyl methylcellulose, 32, 266-

611f

antibacterial drugs for, 176t

267, 267t

intraocular pressure in, 692

external, 389, 389f

Hydroxyzine, 552t

Hypoglycemic drug, 194

internal, 389-390, 390f

Hygiene, eyelid, 384b

Hypopyon, corneal ulcer with, 521f

Hormone replacement therapy, 755t

Hyoscine, 130

Hypotensive drug, 139-173

reduced tear production and,

Hyperacute bacterial conjunctivitis,

adrenergic agonist as

714-715

449-451, 450f

?2 receptor agonist, 153-154

Hormone therapy for tear stimulation,

Hyperemia

apraclonidine, 154-155

275

in anterior uveitis, 590

brimonidine, 155-158, 156f, 157f, 158f

Horn, cutaneous, 400, 400f

in atopic keratoconjunctivitis, 567

beta-blocker as, 145-153

Horner’s syndrome, 352-357

conjunctival

carteolol, 152-153, 153f

diagnosis of, 353-357

bacterial infection and, 445

choice of, 153, 153t

apraclonidine test in, 355-356

Horner’s syndrome and, 354

levobunolol, 150-151

clinical evaluation in, 353-355,

inflammation and, 440t

metipranolol, 152

354b, 354f

latanoprost and, 142

systemic effects of, 9t

cocaine test in, 355, 356f, 357t

in episcleritis, 576

timolol, 145-150, 146t, 148b, 149f

hydroxyamphetamine test in, 355-

Hypereosinophilia in toxocariasis, 629-630

carbonic anhydrase inhibitor as, 158-

356, 356f, 357t

Hyperfluorescence, 618-619, 618f

167. See also Carbonic anhydrase

phenylephrine test in, 356-357

Hyperlaxity of eyelid, 406-408, 407f

inhibitor

sweat test in, 354

Hypermetabolism, 652. See also Thyroid-

for cataract surgery, 603

etiology of, 353b

related orbitopathy

cholinergic agonist as, 167-170

management of, 357, 358f

Hyperopia

classification of, 167b

overview of, 352-353

amblyopia with, 664

for glaucoma, 168-170, 168t, 171b

Hospitalization for corneal ulcers, 524

mitotic agents and, 665

pilocarpine, 168-170, 168t, 171b

HPGuar, 269

Hyperosmolar tears, 269

prostaglandin analogue as, 139-145

Human immunodeficiency virus, 204,

Hyperosmotic agent, 279-280, 280t, 282f

bimatoprost, 144-145, 145f

206t-207t

in glaucoma, 694

latanoprost, 139-143, 140b, 140f,

cytomegalovirus retinitis in, 624

glucose as, 281

141b, 142f, 145f

herpes zoster ophthalmicus and, 394,

glycerin as, 280-281, 280t

travoprost, 143-144, 145f

396

sodium chloride as, 279-280, 280t, 281f

Hypotonic tears, 269

toxoplasmosis and, 628

Hypersensitivity

Hypotony, after cataract surgery, 607, 607f

Human leukocyte antigen

in Adie’s syndrome, 359-360

I

in thyroid disease, 645

to aspirin, 98-99

in uveitis, 598

to bacitracin, 185

Iatrogenic disorder. See also Drug-

Human papilloma virus infection, 399-

to cephalosporin, 183

induced disorder

401, 400f

denervation, in Adie’s syndrome, 359

dapiprazole for, 121

Hutchinson’s sign, 455, 456f

to fluoroquinolones, 196

drug administration causing, 8

Hydrochlorothiazide

to local anesthetic, 91-93, 92f, 93

Ibandronate, 753t

myopia caused by, 720

to opioid, 107

Ibuprofen

reduced tear production and, 715

to penicillin, 182

adverse effects of, 751t

Hydrocodone

to tetracyclines, 191

for child, 109t

formulations of, 105t

Hypersensitivity reaction, 245-247, 246t,

formulation of, 102t

pharmacological properties of, 104t,

247t

Idiopathic episcleritis, 575

105

in allergic eye disease, 549

Idiosyncrasy, drug, 703-704

Hydromorphone, 105t

in contact dermatitis of eyelid, 570

Idoxuridine, 197

Hydrops, 490, 491f, 492-493, 492f

Hypertension

Imaging

Hydrostatic massage, 430, 430f

intracranial, tetracyclines and, 190

anterior segment ocular coherence

Hydroxyamphetamine

ocular

tomography, 675

in anisocoria evaluation, 352t

as cataract surgery complication, 608

computed tomography

clinical uses of, 117-118

corticosteroid induced, 229-232, 241f

in myasthenia gravis, 375, 375f

contraindications to, 119

Hyperthyroidism, Graves, 643-662. See

in thyroid-related orbitopathy, 650-

dapiprazole and, 120

also Thyroid-related orbitopathy

651, 651f

pharmacology of, 117

Hypertonic agent

magnetic resonance, 650-651, 651f

side effects of, 119

in bullous keratopathy, 493-494

optical coherence tomography

Hydroxychloroquine, 749t

in Fuchs’ dystrophy, 489

in glaucoma, 679, 679t

corneal effects of, 705

in recurrent corneal erosion, 505-506

in uveitis, 599